Trial reportCirculation2013
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.
Trial report in Circulation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00948987 (Mechanism Based Resistance to Aspirin), which is not on this map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mechanism Based Resistance to Aspirin
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- Efficacy and safety of eight typesFrontiers in pharmacology · 2022Pooled it
- Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis.Journal of neurology · 2020Pooled it
- Pharmacokinetic Study of Enteric-Coated Sustained-Release Aspirin Tablets in Healthy Chinese Participants.Drug design, development and therapy · 2023Trial
- Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function.British journal of clinical pharmacology · 2022Trial
- In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method.Scientific reports · 2021Trial
- Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.Journal of thrombosis and thrombolysis · 2019Trial
- Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events.BMC medical genomics · 2018Trial
- Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus.Prostaglandins, leukotrienes, and essential fatty acids · 2013Trial
- Physiology and Pathophysiology of Marathon Running: A narrative Review.Sports medicine - open · 2025Review
- The Impact of Single Nucleotide Polymorphisms and Other Mechanisms on Aspirin Resistance.Cardiovascular & hematological disorders drug targets · 2025Review
- Should We Use Aspirin or P2YCurrent atherosclerosis reports · 2024Review
- Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis.Current cardiology reports · 2023Review
- Antiplatelet Resistance: A Review of Concepts, Mechanisms, and Implications for Management in Acute Ischemic Stroke and Transient Ischemic Attack.Stroke (Hoboken, N.J.) · 2023Review
- Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Fifty years with aspirin and platelets.British journal of pharmacology · 2023Review
- Appropriate use of antiplatelet medications following transient ischemic attacks and stroke: a 9-year study from the Middle East.Frontiers in neurology · 2023Article
- The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.Medicina (Kaunas, Lithuania) · 2022Observational
- The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study.European journal of clinical pharmacology · 2022Article
- Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2022Review
- Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation.Clinical pharmacokinetics · 2022Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLow dose aspirin reduces the secondary incidence of myocardial infarction and stroke. Drug resistance to aspirin might result in treatment failure. Despite this concern, no clear definition of aspirin resistance has emerged, and estimates of its incidence have varied remarkably. We aimed to determine the commonality of a mechanistically consistent, stable, and specific phenotype of true pharmacological resistance to aspirin-such as might be explained by genetic causes. METHODS AND
resultsHealthy volunteers (n=400) were screened for their response to a single oral dose of 325-mg immediate release or enteric coated aspirin. Response parameters reflected the activity of the molecular target of aspirin, cyclooxygenase-1. Individuals who appeared aspirin resistant on 1 occasion underwent repeat testing, and if still resistant were exposed to low-dose enteric coated aspirin (81 mg) and clopidogrel (75 mg) for 1 week each. Variable absorption caused a high frequency of apparent resistance to a single dose of 325-mg enteric coated aspirin (up to 49%) but not to immediate release aspirin (0%). All individuals responded to aspirin on repeated exposure, extension of the postdosing interval, or addition of aspirin to their platelets ex vivo.
conclusionsPharmacological resistance to aspirin is rare; this study failed to identify a single case of true drug resistance. Pseudoresistance, reflecting delayed and reduced drug absorption, complicates enteric coated but not immediate release aspirin administration. CLINICAL
trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00948987.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.